{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:26:02Z","timestamp":1777555562021,"version":"3.51.4"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"DOI":"10.3389\/fmolb.2020.00226","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:19:55Z","timestamp":1598933995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses"],"prefix":"10.3389","volume":"7","author":[{"given":"Luca","family":"Vangelista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Secchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2.","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1136.e18","DOI":"10.1016\/j.cell.2019.04.01","article-title":"A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface.","volume":"177","author":"Bangaru","year":"2019","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy.","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-020-00777-5","article-title":"COVID-19: therapeutics and their toxicities.","author":"Chary","year":"2020","journal-title":"J. Med. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9s","article-title":"Convalescent plasma as a potential therapy for COVID-19.","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050366","article-title":"Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.","volume":"7","author":"Elshabrawy","year":"2012","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1742457","article-title":"Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors.","volume":"12","author":"Fan","year":"2020","journal-title":"MAbs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08-020312","article-title":"Dengvaxia controversy: impact on vaccine hesitancy.","volume":"8","author":"Fatima","year":"2018","journal-title":"J. Glob. Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMe2002387","article-title":"Covid-19 - navigating the uncharted.","volume":"382","author":"Fauci","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","article-title":"Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.","volume":"3","author":"Flyak","year":"2018","journal-title":"Nat. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"363.e10","DOI":"10.1016\/j.immuni.2018.06.018","article-title":"Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein.","volume":"49","author":"Gilchuk","year":"2018","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"388.e12","DOI":"10.1016\/j.immuni.2020.01.001","article-title":"Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization.","volume":"52","author":"Gilchuk","year":"2020","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.34172\/ijoem.2020.1977","article-title":"Preparedness and lessons learned from the novel coronavirus disease.","volume":"11","author":"Gudi","year":"2020","journal-title":"Int. J. Occup. Environ. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement.","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","article-title":"Vaccine-induced enhancement of viral infections.","volume":"27","author":"Huisman","year":"2009","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19.","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S0140-6736(20)30559-6","article-title":"Will COVID-19 generate global preparedness?","volume":"395","author":"Jacobsen","year":"2020","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00344","article-title":"The quest for a truly universal influenza vaccine.","volume":"9","author":"Jang","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes.","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.coviro.2019.01.003","article-title":"Achieving cross-reactivity with pan-ebolavirus antibodies.","volume":"34","author":"King","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coviro.2016.02.002","article-title":"Novel universal influenza virus vaccine approaches.","volume":"17","author":"Krammer","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination.","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.copbio.2007.10.011","article-title":"Human monoclonal antibodies by immortalization of memory B cells.","volume":"18","author":"Lanzavecchia","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed.","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease.","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease Therapeutics.","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.15698\/cst2020.04.216","article-title":"Coronavirus infections: epidemiological, clinical and immunological features and hypotheses.","volume":"4","author":"Raoult","year":"2020","journal-title":"Cell Stress"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/imr.12481","article-title":"Native-like Env trimers as a platform for HIV-1 vaccine design.","volume":"275","author":"Sanders","year":"2017","journal-title":"Immunol. Rev."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A vaccine against Ebola virus.","volume":"181","author":"Saphire","year":"2020","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"938.e13","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection.","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.jmb.2019.04.016","article-title":"Protein and glycan mimicry in HIV vaccine design.","volume":"431","author":"Seabright","year":"2019","journal-title":"J. Mol. Biol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104562","article-title":"New antibody-based prevention and treatment options for influenza.","volume":"170","author":"Sedeyn","year":"2019","journal-title":"Antiviral Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and broadly neutralizing antibodies for HIV-1 prevention.","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients.","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation and pandemic formation.","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb4420","article-title":"The costs of secrecy.","volume":"367","author":"Thorp","year":"","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7248","article-title":"Underpromise, overdeliver.","volume":"367","author":"Thorp","year":"","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000139","article-title":"Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains.","volume":"17","author":"Turner","year":"2019","journal-title":"PLoS Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/imcb.12312","article-title":"The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens.","volume":"98","author":"Vanderven","year":"2020","journal-title":"Immunol. Cell. Biol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00135","article-title":"Broadly protective strategies against influenza viruses: universal vaccines and therapeutics.","volume":"11","author":"Vogel","year":"2020","journal-title":"Front. Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"281.e6","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein.","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion.","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry.","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection.","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11684-019-0721-9","article-title":"Broadly neutralizing antibodies and vaccine design against HIV-1 infection.","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Med."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2.","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0764-y","article-title":"Recent advances in \u201cuniversal\u201d influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head.","author":"Wang","year":"2020","journal-title":"Front. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"878.e15","DOI":"10.1016\/j.cell.2017.04.03","article-title":"Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses.","volume":"169","author":"Wec","year":"2017","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200537","article-title":"Forty years with coronaviruses.","volume":"217","author":"Weiss","year":"2020","journal-title":"J. Exp. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41594-019-0191-4","article-title":"Structural basis of broad ebolavirus neutralization by a human survivor antibody.","volume":"26","author":"West","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2020.1741313","article-title":"Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus.","volume":"10","author":"Wolfe","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"B61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/22221751.2019.1624482","article-title":"Antibodies and vaccines against Middle East respiratory syndrome coronavirus.","volume":"8","author":"Xu","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains.","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.03.063","article-title":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak.","volume":"30","author":"Zhang","year":"2020","journal-title":"Curr. Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","article-title":"A genomic perspective on the origin and emergence of SARS-CoV-2.","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"891.e15","DOI":"10.1016\/j.cell.2017.04.038","article-title":"Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability.","volume":"169","author":"Zhao","year":"2017","journal-title":"Cell"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2020.00226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:19:59Z","timestamp":1598933999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2020.00226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":67,"alternative-id":["10.3389\/fmolb.2020.00226"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2020.00226","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"article-number":"226"}}